447 related articles for article (PubMed ID: 22612517)
1. Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients.
Genazzani AD; Prati A; Santagni S; Ricchieri F; Chierchia E; Rattighieri E; Campedelli A; Simoncini T; Artini PG
Gynecol Endocrinol; 2012 Dec; 28(12):969-73. PubMed ID: 22612517
[TBL] [Abstract][Full Text] [Related]
2. Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients.
Genazzani AD; Santagni S; Rattighieri E; Chierchia E; Despini G; Marini G; Prati A; Simoncini T
Gynecol Endocrinol; 2014 Jun; 30(6):438-43. PubMed ID: 24601829
[TBL] [Abstract][Full Text] [Related]
3. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study.
Artini PG; Di Berardino OM; Papini F; Genazzani AD; Simi G; Ruggiero M; Cela V
Gynecol Endocrinol; 2013 Apr; 29(4):375-9. PubMed ID: 23336594
[TBL] [Abstract][Full Text] [Related]
4. Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Croze ML; Soulage CO
Biochimie; 2013 Oct; 95(10):1811-27. PubMed ID: 23764390
[TBL] [Abstract][Full Text] [Related]
5. Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS.
Pizzo A; Laganà AS; Barbaro L
Gynecol Endocrinol; 2014 Mar; 30(3):205-8. PubMed ID: 24351072
[TBL] [Abstract][Full Text] [Related]
6. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome.
Genazzani AD; Lanzoni C; Ricchieri F; Jasonni VM
Gynecol Endocrinol; 2008 Mar; 24(3):139-44. PubMed ID: 18335328
[TBL] [Abstract][Full Text] [Related]
7. Metformin therapy increases insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome.
Baillargeon JP; Iuorno MJ; Jakubowicz DJ; Apridonidze T; He N; Nestler JE
J Clin Endocrinol Metab; 2004 Jan; 89(1):242-9. PubMed ID: 14715857
[TBL] [Abstract][Full Text] [Related]
8. Differential insulin response to oral glucose tolerance test (OGTT) in overweight/obese polycystic ovary syndrome patients undergoing to myo-inositol (MYO), alpha lipoic acid (ALA), or combination of both.
Genazzani AD; Prati A; Marchini F; Petrillo T; Napolitano A; Simoncini T
Gynecol Endocrinol; 2019 Dec; 35(12):1088-1093. PubMed ID: 31304823
[TBL] [Abstract][Full Text] [Related]
9. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
[TBL] [Abstract][Full Text] [Related]
10. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.
Nestler JE; Jakubowicz DJ; Reamer P; Gunn RD; Allan G
N Engl J Med; 1999 Apr; 340(17):1314-20. PubMed ID: 10219066
[TBL] [Abstract][Full Text] [Related]
11. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
Wu J; Zhu Y; Jiang Y; Cao Y
Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
[TBL] [Abstract][Full Text] [Related]
12. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
Koo YA; Shin SY; Yoon BK; Choi D
Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
[TBL] [Abstract][Full Text] [Related]
13. Adiponectin levels in women with polycystic ovary syndrome and severe insulin resistance.
Sepilian V; Nagamani M
J Soc Gynecol Investig; 2005 Feb; 12(2):129-34. PubMed ID: 15695109
[TBL] [Abstract][Full Text] [Related]
14. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial.
Costantino D; Minozzi G; Minozzi E; Guaraldi C
Eur Rev Med Pharmacol Sci; 2009; 13(2):105-10. PubMed ID: 19499845
[TBL] [Abstract][Full Text] [Related]
15. Role of inositolphosphoglycan mediators of insulin action in the polycystic ovary syndrome.
Nestler JE; Jakubowicz DJ; Iuorno MJ
J Pediatr Endocrinol Metab; 2000; 13 Suppl 5():1295-8. PubMed ID: 11117673
[TBL] [Abstract][Full Text] [Related]
16. Neuropeptide Y, leptin, galanin and insulin in women with polycystic ovary syndrome.
Baranowska B; Radzikowska M; Wasilewska-Dziubińska E; Kapliński A; Roguski K; Płonowski A
Gynecol Endocrinol; 1999 Oct; 13(5):344-51. PubMed ID: 10599552
[TBL] [Abstract][Full Text] [Related]
17. Glucose intolerance in Japanese patients with polycystic ovary syndrome.
Kurioka H; Takahashi K; Miyazaki K
Arch Gynecol Obstet; 2007 Mar; 275(3):169-73. PubMed ID: 16972071
[TBL] [Abstract][Full Text] [Related]
18. Analysis of clinical characteristics in large-scale Chinese women with polycystic ovary syndrome.
Shi Y; Guo M; Yan J; Sun W; Zhang X; Geng L; Xu L; Chen Z
Neuro Endocrinol Lett; 2007 Dec; 28(6):807-10. PubMed ID: 18063948
[TBL] [Abstract][Full Text] [Related]
19. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction.
Papaleo E; Unfer V; Baillargeon JP; De Santis L; Fusi F; Brigante C; Marelli G; Cino I; Redaelli A; Ferrari A
Gynecol Endocrinol; 2007 Dec; 23(12):700-3. PubMed ID: 17952759
[TBL] [Abstract][Full Text] [Related]
20. Myo-inositol modulates insulin and luteinizing hormone secretion in normal weight patients with polycystic ovary syndrome.
Genazzani AD; Santagni S; Ricchieri F; Campedelli A; Rattighieri E; Chierchia E; Marini G; Despini G; Prati A; Simoncini T
J Obstet Gynaecol Res; 2014 May; 40(5):1353-60. PubMed ID: 24606639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
